Search

Search Results

• TARGETING DORMANT BACILLI TO FIGHT TUBERCULOSIS

  Lanfranco Fattorini, Giovanni Piccaro, Alessandro Mustazzolu, Federico Giannoni

  e2013072

  2013-11-19

  https://doi.org/10.4084/mjhid.2013.072

  3025

  PDF: 1023

  HTML: 3073

• THE TRAGEDY CAUSED BY FAKE ANTIMALARIAL DRUGS

  Pierre Ambroise-Thomas

  e2012027

  2012-05-04

  https://doi.org/10.4084/mjhid.2012.027

  2746

  PDF: 1076

  HTML: 1909

• PROPHYLAXIS OF MALARIA

  Eli Schwartz

  e2012045

  2012-06-29

  https://doi.org/10.4084/mjhid.2012.045

  3001

  PDF: 1018

  HTML: 17792

  Figures SChwartz: 163

• A PROSPECTIVE, OBSERVATIONAL STUDY OF ADVERSE REACTIONS TO DRUG REGIME FOR MULTI-DRUG RESISTANT PULMONARY TUBERCULOSIS IN CENTRAL INDIA.

  Dr. Rohan C. Hire, Dr. A. S. Kale, Dr. G. N. Dakhale, Dr. Nilesh N. Gaikwad

  e2014061

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.061

  1802

  PDF: 1065

  HTML: 3810

• MALARIA AND HIV IN ADULTS: When The Parasite runs into The Virus

  Emanuele Focà, Silvia Odolini, Nigritella Brianese, Gianpiero Carosi

  e2012032

  2012-05-07

  https://doi.org/10.4084/mjhid.2012.032

  2687

  PDF: 1002

  HTML: 2265

• THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone

  George J Kontoghiorghes, Marios Kleanthous, Christina N. Kontoghiorghe

  e2020011

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.011

  2396

  PDF: 1580

  HTML: 620

• Guest Editor: G. Castaman AGING WITH HEMOPHILIA: THE CHALLENGE OF APPROPRIATE DRUG PRESCRIPTION Hemophilia and aging

  Pier Mannuccio Mannucci

  e2019056

  2019-08-29

  https://doi.org/10.4084/mjhid.2019.056

  1674

  PDF: 1436

  HTML: 242

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

  Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani

  e2012069

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.069

  2520

  PDF: 710

  HTML: 1530

• Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs

  Giuseppe Vittorio De Socio, Antonio D'Avolio, Alessio Sgrelli, Lorena Baietto, Lisa Malincarne, Giovanni Di Perri, Franco Baldelli

  e2012007

  2012-01-23

  https://doi.org/10.4084/mjhid.2012.007

  1577

  PDF: 776

  HTML: 814

  tile page: 161

  Table 1: 161

• Graves’ disease thyrotoxicosis and propylthiouracil related agranulocytosis successfully treated with therapeutic plasma exchange and g-csf followed by total thyroidectomy.

  Anna Candoni

  e2017058

  2017-10-16

  https://doi.org/10.4084/mjhid.2017.058

  2889

  PDF: 872

  HTML: 1408

  Fig.1: 164

  Fig.2: 172

• ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS

  Lourdes Vazquez

  e2016040

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.040

  4289

  PDF: 1369

  HTML: 2038

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  4036

  PDF: 1146

  HTML: 1933

  Fig.1: 217

  Fig. 2: 109

  Table 1: 201

  Table2: 218

  Table 3: 199

• TUBERCULOSIS IN CHILDREN

  Susanna Esposito

  e2013064

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.064

  3120

  PDF: 1314

  HTML: 4817

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277647

  PDF: 1788

  HTML: 3862

• SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

  Massimo Breccia, Giuliana Alimena

  e2014003

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.003

  3139

  PDF: 1215

  HTML: 3469

• HOW THE HEMOSTASIS LABORATORY CAN HELP CLINICIANS TO MANAGE PATIENTS ON ORAL ANTICOAGULANTS

  Armando Tripodi

  e2024027

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.027

  993

  PDF: 1342

  HTML: 128

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2105

  PDF: 1685

  HTML: 374

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1703

  PDF: 1655

  HTML: 797

• EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS IN THE MEDITERRANEAN AREA

  Ulrike Binder, Cornelia Lass-Flörl

  e2011016

  2011-03-30

  https://doi.org/10.4084/mjhid.2011.016

  2224

  PDF: 978

  HTML: 4887

• MANAGING INVASIVE FUNGAL INFECTIONS DURING ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION: A 2025 UPDATE

  Martina Quattrone, Alessia Di Pilla, Sara Brunetti, Antonio Giordano, Luana Fianchi, Livio Pagano, Marianna Criscuolo

  e2025064

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.064

  2048

  PDF: 829

  HTML: 162

• ADVANCES IN THE TREATMENT OF MALARIA

  Francesco Castelli, Lina Rachele Tomasoni, Alberto Matteelli

  e2012064

  2012-10-03

  https://doi.org/10.4084/mjhid.2012.064

  2835

  PDF: 1120

  HTML: 5990

• THE DARK SIDE OF THE COVID-19 TREATMENTS ON MYCOBACTERIUM TUBERCULOSIS INFECTION

  Flavio De Maio, Delia Mercedes Bianco, Giovanni Delogu

  e2022021

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.021

  1253

  PDF: 743

  HTML: 226

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1654

  PDF: 644

  HTML: 2430

• SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis

  Roberta Zanotti, Massimiliano Bonifacio, Ilaria Tanasi, Donatella Schena, Giovanni Orsolini, Morena Tebaldi, Lara Crosera, Francesca Mastropaolo, Elisa Olivieri, Dr. Patrizia Bonadonna

  e2021068

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.068

  1514

  PDF: 936

  HTML: 222

• TUBERCULOSIS IN TROPICAL AREAS AND IMMIGRANTS

  Lorenzo Zammarchi, Filippo Bartalesi, Alessandro Bartoloni

  e2014043

  2014-05-31

  https://doi.org/10.4084/mjhid.2014.043

  3300

  PDF: 1313

  HTML: 6189

• INVASIVE CANDIDA INFECTIONS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES AND HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: CURRENT EPIDEMIOLOGY AND THERAPEUTIC OPTIONS.

  Corrado Girmenia, Erica Finolezzi, Vincenzo Federico

  e2011013

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.013

  2258

  PDF: 962

  HTML: 1854

• HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK

  Katleen de Gaetano Donati, Roberto Cauda, Licia Iacoviello

  e2010034

  2010-11-10

  https://doi.org/10.4084/mjhid.2010.034

  1815

  PDF: 794

  HTML: 3599

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  3899

  Suppl. Files: 1105

  PDF: 1061

  Html: 170

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4295

  PDF: 1480

  HTML: 3618

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4307

  PDF: 1487

  HTML: 1547

  Untitled: 225

• TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE

  Vikram Mathews, Ezhilarasi Chendamarai, Biju George, Auro Viswabandya, Alok Srivastava

  e2011056

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.056

  3629

  PDF: 918

  HTML: 4451

• OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES

  Jon Salmanton-Garcia, Francesco Marchesi, Oliver A. Cornely, Jannik Stemler, Pierantonio Menna

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.022

  1005

  PDF: 1178

  Suppl. Files: 146

  HTML: 67

• TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti

  e2014005

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.005

  3305

  PDF: 1463

  HTML: 3997

• ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Angelo Michele Carella

  e2012059

  2012-10-02

  https://doi.org/10.4084/mjhid.2012.059

  2018

  PDF: 795

  HTML: 1045

• ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS

  George Petrikkos, Miranda Drogari-Apiranthitou

  e2011012

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.012

  2803

  PDF: 944

  HTML: 7330

• DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA

  Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos

  e2019016

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.016

  1867

  PDF: 1111

  HTML: 253

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  2032

  PDF: 1112

  HTML: 179

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2131

  PDF: 730

  HTML: 1628

• THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS INFECTION.

  Giovanni Delogu, Michela Sali, Giovanni Fadda

  e2013070

  2013-11-15

  https://doi.org/10.4084/mjhid.2013.070

  10570

  PDF: 6338

  HTML: 21782

• CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA

  Michele Bibas, Jorge J Castillo

  e2014064

  2014-10-22

  https://doi.org/10.4084/mjhid.2014.064

  2593

  PDF: 1605

  HTML: 2354

  Table1: 188

• "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

  Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro

  e2010013

  2010-06-01

  https://doi.org/10.4084/mjhid.2010.013

  1401

  PDF: 658

  HTML: 1507

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1508

  PDF: 1334

  HTML: 113

• CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment

  Michele Malagola, Raffaella Greco, Stella Santarone, Anna Paola Iori, Luisa Quatrocchi, Walter Barberi, Bruzzese Antonella, Salvatore Leotta, Alessandra Carotti, Antonio Pierini, Simon Bernardi, Enrico Morello, Nicola Polverelli, Alessandro Turra, Federica Cattina, Lisa Gandolfi, Benedetta Rambaldi, Francesca Lorentino, Francesca Serio, Annalisa Natale, Giuseppe Milone, Andrea Velardi, Robin Foà, Fabio Ciceri, Domenico Russo, Jacopo Peccatori

  e2019048

  2019-08-29

  https://doi.org/10.4084/mjhid.2019.048

  1927

  PDF: 1159

  HTML: 265

• TUBERCULOSIS IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS.

  Silvia F Costa, Jessica Ramos, Marjorie Vieira Batista

  e2013061

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.061

  2622

  PDF: 940

  HTML: 3603

• CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Rafael de la Camara

  e2016031

  2016-06-20

  https://doi.org/10.4084/mjhid.2016.031

  4787

  PDF: 1776

  HTML: 2704

  Untitled: 214

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN FOLLICULAR LYMPHOMAS

  Mónica Cabrero, Alba Redondo, Alejandro Martin, Dolores Caballero

  e2012074

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.074

  2145

  PDF: 729

  HTML: 1069

• Severe Acute Hepatitis B Treated with Entecavir

  Giuseppe Vittorio Luigi De Socio, Alessio Sgrelli, Andrea Tosti, Franco Baldelli

  e2011010

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.010

  1524

  PDF: 785

  HTML: 2473

  Figure: 167

  Title page: 172

  disclosure: 104

• Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists

  Monica Carpenedo, Dr, Dr, Dr

  e2023021

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.021

  1172

  PDF: 1068

  HTML: 688

• SHORT TERM ADVANTAGES OF A PUBLIC-PRIVATE PARTNERSHIP FOR TUBERCULOSIS IN GUINEA BISSAU: REDUCTION OF MORTALITY AND INCREASED DIAGNOSTIC CAPACITY

  Fina Vieira, Mamadu Saliu Sanha, Fabio Riccardi, Raffaella Colombatti

  e2014049

  2014-06-29

  https://doi.org/10.4084/mjhid.2014.049

  1400

  PDF: 911

  HTML: 1281

  Untitled: 173

• INFECTIOUS AETIOLOGY OF MARGINAL ZONE LYMPHOMA AND ROLE OF ANTI-INFECTIVE THERAPY

  Salvatore Perrone, Gianna Maria D'Elia, Alessandro Pulsoni

  e2016006

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.006

  4430

  PDF: 1325

  HTML: 2158